Northwest Biotherapeutics
@nwbio.com
Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. Currently approved cancer treatments are frequently ineffective, can cause undesirable side effects and provide marginal clinical benefits. The Company’s approach in developing cancer therapies utilizes its expertise in the biology of dendritic cells, which are a type of white blood cell that activate the immune system. The Company’s cancer therapies have been demonstrated in clinical trials to significantly extend both time to recurrence and survival, whilst providing a superior quality of life with no debilitating side effects when compared with current therapies. The Company’s platform technology, DCVax®, uses a patient’s own dendritic cells, the starter engine of the immune system. The dendritic cells are extracted from the body, loaded with tumor biomarkers or ‘‘antigens’’, thereby creating a personalized therapeutic vaccine. Injection of these cells back into the patient initiates a potent immune response against cancer cells, resulting in delayed time to progression and prolonged survival. The Company’s lead product candidate is DCVax®-Brain which targets Glioblastoma Multiforme (‘‘GBM’’), the most lethal form of brain cancer. DCVax®-Brain has entered a Phase II FDA-allowed clinical trial, which is designed and powered as a pivotal trial (i.e. a trial from which a company may go directly to product approval). Following this trial, the Company anticipates filing a biologic license application (or ‘‘BLA’’) with the FDA for DCVax®-Brain. DCVax®-Prostate, which targets hormone independent (i.e. late stage) prostate cancer, has also been cleared by the FDA to commence a Phase III clinical trial, which is also designed and powered as a pivotal trial.
Northwest Biotherapeutics's Company Logos
Northwest Biotherapeutics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#72A4BD
Glacier
114, 164, 189
200, 36, 59
40, 13, 0, 26
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#3E9237
Apple
62, 146, 55
115, 45, 39
58, 0, 62, 43
About Northwest Biotherapeutics
Northwest Biotherapeutics is a clinical stage biotechnology company specializing in personalized cancer vaccines for the treatment of various solid tumor cancers. Their innovative DCVax® technology utilizes activated dendritic cells to stimulate the patient's immune system and target cancer cells effectively. Their product lineup includes DCVax® – L, DCVax® – Direct, and DCVax® – Prostate, which offer targeted therapies for specific cancer types.
DCVax® – L is currently in Phase III clinical trials for GBM Brain Cancer, while DCVax® – Direct is in Phase I/II trials for all types of inoperable solid tumor cancers. Northwest Biotherapeutics prides itself on its commitment to patient care and has received positive recognition in the medical community with patient stories and physician comments supporting their immunotherapy approach. The company also actively engages with investors and the media, providing press releases, SEC filings, and webcasts to keep stakeholders informed.
With a strong focus on research and development, Northwest Biotherapeutics continues to lead the way in revolutionizing cancer treatment with their cutting-edge products and personalized approach to care
Brand industry
Health
Company type
Suggest company type
Year founded
Suggest founded year
Company size
11-50 employees
Related Brands
Tags
Personalized cancer vaccines
Dendritic cell immunotherapy
Solid tumor oncology therapeutics
DCVax® platform technology
Clinical trial oncology pipeline
